Google
XERS 株価分析 — Xeris Pharmaceuticals Inc (Healthcare >> Drug Manufacturers - Specialty & Generic)
XERS に関するよくある質問
XERSのPER（株価収益率）は？
Xeris Pharmaceuticals Inc（XERS）は現在PER 100.72倍で取引されています。
XERSのROE（自己資本利益率）は？
Xeris Pharmaceuticals IncのROEは92.29%です。
XERSの配当利回りは？
Xeris Pharmaceuticals Incの配当利回りは0.00%です。
XERSの品質スコア（Quality Score）は？
当社のAIはXERSの総合財務品質を100点中69点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
XERSは今が買い時ですか？
当社AIのタイミングスコアは100点中66点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
XERSはどのセクターに属しますか？
Xeris Pharmaceuticals IncはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます（NASDAQ市場）
XERS AI Analysis Summary
Our AI summary for XERS: Xeris Pharmaceuticals Inc (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 100.72, ROE of 92.29%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 8.19
Price
0.06
(0.74%)
Day Change
|
|
|---|
XERS, ファンダメンタルスコアはok ( ファンダメンタル = 69) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
P/Eが高い。割高銘柄。
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
3095
|
| Magic Formula Rank by ROE |
3095
|
| Magic Formula Rank by ROIC |
3093
|
| Price | 8.19 |
| PBV / Sector |
107.88 / 10.04
|
| Earning Per Share | 0.07 |
| PE / Sector |
100.72 / 32.60
|
| PEG or PE/Growth / Sector |
-1.97 / -0.13
|
| Average 1M Daily Value |
13.24 M
GREAT
|
| Average 1W Daily Value |
12.28 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
58% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:01:06 |
| Symbol | XERS |
| Name | XERIS PHARMACEUTICALS INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 172.64 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,403.58 / 10,527.15 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1375 West Fulton Street, Chicago, IL, United States, 60607
Phone: 844 445 5704
Website: https://www.xerispharma.com
Employees: 435
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
